In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ocular Therapeutix Inc.

Latest From Ocular Therapeutix Inc.

Code Break: Medicare Accelerates ‘J-Code’ Assignment To Boost Uptake Of New Drugs

Manufacturers can apply for permanent Medicare reimbursement codes on a quarterly basis rather than annually going forward to allow for more frequent coding awards. Recently about two dozen drugs, including three biosimilars, received permanent codes earlier than usual.

Medicare Reimbursement

How Ocular Therapeutix Recovered From US FDA’s Second Dextenza CRL

A new approach, total dedication and lots of practice made a difference for the Massachusetts start-up after FDA approval was twice deferred over manufacturing quality concerns.

Drug Review Manufacturing

Keeping Track: US FDA Closes Out First Half Of 2019 With CRL For Edsivo, But A Burst Of Supplemental Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.

Approvals Drug Review

Finance Watch: Anchiano, TCR2, Hoth And Stealth Make Seven US Biopharma IPOs For 2019

Public Company Edition: Four more IPOs in the US bring the year's total to seven – all in February. Also, Agenus launched its digital security offering, MacroGenics leads recent follow-on offerings and four companies reveal new job cuts.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Medical Devices
    • Biomaterials
    • Implantable Devices
    • Surgical Equipment & Devices
      • Surgical Sealants
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
  • Therapeutic Areas
  • Inflammation
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • I-Therapeutix Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ocular Therapeutix Inc.
  • Senior Management
  • Antony Mattessich, Pres. & CEO
    Donald Notman, CFO
    Peter Jarrett, PhD, CSO
    Christopher White, SVP, Bus. & Corp. Dev.
    Chad Brines, VP, Sales
    Patricia Kitchen, COO
  • Contact Info
  • Ocular Therapeutix Inc.
    Phone: (877) 628-8998
    15 Crosby Dr.
    Bedford, MA 01730